A professor had a $2.4m grant to study Black maternal health. Then Trump was elected
'It was heartbreaking,' Slaughter-Acey told the Guardian, 'and honestly, infuriating given the high rates of maternal and infant mortality in this country.'
The cancellation came as the Trump administration terminated 1,902 NIH grants totalling more than $4.4bn between his January inauguration and the end of July, according to Grant Witness data. NIH followed guidance from the so-called 'department of government efficiency' (Doge) and Trump's executive orders to cut costs. Additionally, in April, the Trump administration let go of a majority of the staff at the federal Division of Reproductive Health, a Centers for Disease Control and Prevention (CDC) office that collects data on maternal experiences. It also surveils pregnancy-related deaths in an effort to reduce infant mortality and improve health outcomes for mothers and their children.
Related: 'A scary time to be a scientist': how medical research cuts will hurt the maternal mortality crisis
Slaughter-Acey's several-year study funded by a more than $2.4m NIH grant aimed to look at how social and biological factors affect outcomes for more than 500 Black women in Detroit. The grant termination froze the team's more than $581,000 remaining funding. Through blood samples and surveys of Black mothers and grandmothers, Slaughter-Acey and her team aimed to understand if social environments accelerated how bodies physiologically age, otherwise known as biological ageing, which may lead to adverse pregnancy outcomes for Black women. She said that the research is 'designed to tell us how social environment and the pathways that social environment affects us physiologically, to then increase this risk that Black moms and Black babies have with respect to pregnancy'.
While most studies that look at racism only focus on one point in time, Slaughter-Acey said that hers was 'the first study to comprehensively examine how exposure to structural, cultural and intergenerational racism throughout a Black woman's life impacts her epigenome and her child's birth outcomes.' It was also innovative because Black women are underrepresented in epigenomic studies, a field where researchers look at how environment and behavior impacts a person's genes, said Slaughter-Acey, due to medical mistrust and experiences of racism in the healthcare system.
'When science is silenced, communities suffer'
The NIH-grant cancellation in late March followed the release of data from the CDC revealing that Black women were the only race or ethnic group who didn't experience a decline in deaths from pregnancy related causes in 2023. Out of every 100,000 live births, 50.3 Black mothers died, compared with 14.5 deaths for white people, 12.4 for Latinos and 10.7 for Asians. The NIH didn't respond to a request for comment.
Slaughter-Acey fears that the grant-cancellation signals that research and efforts to close the maternal death gap are at risk of coming to a standstill under the Trump administration. Other NIH grants that have been terminated include one that looked at prenatal exposure to public drinking water contaminants and a study that analyzed why women of color die of cervical cancer at a disproportionate rate. On Thursday, the Trump administration froze UCLA research grants from federal agencies including NIH and the National Science Foundation totaling nearly $200m, accusing the university of antisemitism and discrimination in admissions.
'It's part of a larger pattern of political interference in science that puts the health of all people at risk, especially vulnerable populations,' Slaughter-Acey said. The study 'is about understanding the root causes of poor maternal and infant health in this country – something that affects all of us, regardless of race or background. When science is silenced, communities suffer'.
Still, Slaughter-Acey and her team are hopeful that the study will continue for years to come as they search for alternative funding sources, including donations. On Slaughter-Acey's LinkedIn page, she called upon her followers to donate to the University of North Carolina Department of Epidemiology, and to include a note that they support Slaughter-Acey's work, or the name of the study, 'LIFE-2'.
'The voices of these 500 plus moms and babies should not die or be silenced with the termination of this grant,' she told the Guardian. The pull in funding 'is an example of erasure of black mothers and infants'.
There has been some temporary relief. This June, Slaughter-Acey's team received short-term funding from Michigan State University to continue their study over the next few months. Now nearly 600 moms are enrolled in the study, but without additional funding, it will probably pause again at the end of the year.
'We need research that reflects Black women's experiences'
The nearly 600 women who have joined the study were recruited from local delivery hospitals in Detroit, Michigan, in the day or two following childbirth. Slaughter-Acey chose Detroit since she completed her post-doc at the University of Michigan, where she researched the influence of social environments on Black maternal health. Participants for her study, which began in 2021, completed a post-delivery survey where they answered questions about social determinants of health including housing and food insecurity throughout their life.
Along with collecting their blood through a finger prick, researchers also collect the babies' and mothers' birth certificates from the state health department as well as the mothers' blood that was collected at birth and stored in a biobank. About 20% of the babies' grandmothers are also participating in the study by answering questions about the social environment during their pregnancies and their daughters' early childhoods.
The multilevel data collection allows the researchers to create 'this robust and triangulated dataset that includes social determinants of health, like information about food and housing insecurity', Slaughter-Acey said. 'It's capturing a more holistic view than what's been captured previously for moms in terms of maternal and infant health.'
After the moms are discharged from the hospital, the researchers also follow up with a majority of the women eight to 10 weeks after they give birth to ask about their adjustment to motherhood, whether they've received support for breastfeeding, a postpartum healthcare visit, or if they've experienced discrimination from their healthcare providers.
At the time of the funding termination, the research team was in the process of creating a 12-month postpartum checkup with the mothers to help define maternal thriving. 'When we are talking about maternal morbidity and mortality, we're defining maternal health by the absence of disease, by mom not dying, by mom not having a severe morbidity,' Slaughter-Acey said. 'But the field in general does not have a good understanding or even definition of, 'what does maternal thriving look like?' And we need to get past this conversation of maternal survival, and move to thriving.'
More than two years of funding remained in the NIH grant, during which her team had planned to recruit more mothers and to conduct data analysis. They also aimed to create a website for participants to read about the study's findings.
Related: Consent decrees force schools to desegregate. The Trump administration is striking them down
But the data that the team has analyzed thus far has revealed that mothers with a lot of adverse childhood experiences were more likely to have conflict with the father of the child. The finding, Slaughter-Acey said, 'underscores the importance of understanding how the social environment influences relationship dynamics and maybe perinatal outcomes. We know that social support is key during pregnancy'.
The team also found that one in five study participants experienced housing insecurity during their pregnancy, a factor that she said greatly affects perinatal health and is rarely documented in hospital records. They also created a tool to measure racial microagressions from healthcare providers and in the mothers' everyday life, since many in the cohort said that they experienced harmful interactions that Slaughter-Acey said may explain why they felt unsupported.
For Slaughter-Acey, the study findings 'highlight how structural inequities – across housing, healthcare, and personal history – intersect to shape maternal and infant outcomes. And they underscore why we need research that listens to and reflects the full complexity of Black women's experiences.'
NIH research funding will probably continue to take a hit under the Trump administration. A new Trump administration policy requiring that multiyear grants be paid upfront lowers the odds that a research proposal will be accepted. As a result, university labs may close.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
eHealth (EHTH) Q2 Earnings Report Preview: What To Look For
Online health insurance comparison site eHealth (NASDAQ:EHTH) will be reporting results this Wednesday morning. Here's what to expect. eHealth beat analysts' revenue expectations by 13.4% last quarter, reporting revenues of $113.1 million, up 21.7% year on year. It was an exceptional quarter for the company, with a solid beat of analysts' EBITDA estimates and full-year EBITDA guidance exceeding analysts' expectations. It reported 1.16 million users, down 1.8% year on year. Is eHealth a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting eHealth's revenue to decline 29.5% year on year to $46.41 million, a further deceleration from the 1.4% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$1.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. eHealth has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 13.1% on average. Looking at eHealth's peers in the online marketplace segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Shutterstock delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 7.5%, and EverQuote reported revenues up 33.7%, in line with consensus estimates. Shutterstock's stock price was unchanged following the results. Read our full analysis of Shutterstock's results here and EverQuote's results here. Investors in the online marketplace segment have had steady hands going into earnings, with share prices up 1.5% on average over the last month. eHealth is down 22.5% during the same time and is heading into earnings with an average analyst price target of $10 (compared to the current share price of $3.21). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution's MyDataHelps® platform ANN ARBOR, Mich., August 05, 2025--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. "Decentralized trials broaden reach, speed timelines and yield richer real-world evidence," said Vik Kheterpal, MD, a principal at CareEvolution. "LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid." Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. "For people with severe Long Covid, travel can be dangerous," said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. "LoCITT enables even patients with the most severe symptoms to join the search for answers." Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. "We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it," said John Redd, CEO of SILC. "We're hopeful that a remote trial will help us find effective treatments more quickly." CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at View source version on Contacts CareEvolutionpr@ Swati Pandey, SILCspandey@ Anna Andersen, Scripps Researchaanders@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
These 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says
These 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says originally appeared on Men's Fitness. Carbs are not the root of all evil. But when you're in a calorie deficit, they can feel off-limits. The truth is, carbs are the body's main source of fuel. They power our heavy lifting days, energize outdoor runs, and sustain us through everyday life. Still, some carb-heavy foods like bread can be calorie-dense and feel like a trap when you're trying to cut back. Trainer Dan Go shared five low-calorie carb sources that actually help keep you full while you're in a Carbs Potatoes "Potatoes are low in calories, high in fiber—especially with the skin. This makes them incredibly filling, and also their resistant starch and high water content helps you feel satisfied longer," Go says. Blueberries Blueberries may not be the first food that comes to mind when thinking about carbs. But, with their rich fiber and water content, they're a low-calorie carb that's highly satiating. The fiber in blueberries also slows digestion, which keeps you full and helps stabilize blood sugar. Lentils Lentils are small, but their fiber content is mighty. Along with its carb content, they're also a great source of plant protein, high in satiety. Broccoli "The reason I love broccoli is because it's one of the perfect foods to volumize your meals, because it contains a lot of fiber, a lot of water, and it helps you keep full while giving you an incredible nutrient profile," Go says. Rich in vitamin C, K, and folate, eating broccoli helps support your metabolism and digestion. Apples Go calls apples "nature's appetite suppressant." If you need a sweet treat during your calorie deficit, lean on apples. They're high in fiber and low in calories, helping you curb hunger and reduce snacking. Apples are also rich in 5 Surprising Carbs Help You Stay Full and Stick to a Calorie Deficit, Trainer Says first appeared on Men's Fitness on Jul 10, 2025 This story was originally reported by Men's Fitness on Jul 10, 2025, where it first appeared. Solve the daily Crossword